Key result
Switching to a non-fixed combination of perindopril and moxonidine achieved target blood pressure <130/80 mmHg in 64.0% (0.4 mg dose) and 63.6% (0.6 mg dose) of patients with hypertension and metabolic syndrome.
Why the study?
To evaluate the efficacy of a non-fixed perindopril plus moxonidine combination in achieving target blood pressure <130/80 mm Hg in patients with arterial hypertension and metabolic syndrome on two-component therapy.
Does a non-fixed combination of perindopril and moxonidine improve blood pressure control in patients with hypertension and metabolic syndrome?
Observational (n=72)
Open-label
Does a non-fixed combination of perindopril and moxonidine improve blood pressure control in patients with hypertension and metabolic syndrome?
A non-fixed combination of perindopril and moxonidine effectively lowers blood pressure and improves metabolic parameters in patients with hypertension and metabolic syndrome.
May support BP control in hypertension with metabolic syndrome; hypothesis-generating pending randomized confirmation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Недогода et al. (2021) conducted an observational in Arterial hypertension and metabolic syndrome (n=72). Non-fixed combination perindopril and moxonidine vs. Prior two-component antihypertensive therapy was evaluated on Achievement of target blood pressure <130/80 mmHg. Switching to a non-fixed combination of perindopril and moxonidine achieved target blood pressure <130/80 mmHg in 64.0% (0.4 mg dose) and 63.6% (0.6 mg dose) of patients with hypertension and metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: